Patents by Inventor Dean R. Madden

Dean R. Madden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Cystic Fibrosis
    Publication number: 20230338340
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases associated with interaction of proteins with PDZ domain of the CFTR-associated ligand (CAL PDZ or CALP) and/or DH domain on Disabled-2 (Dab2) protein (Dab2-DH). More particularly, this disclosure relates to methods of treating cystic fibrosis.
    Type: Application
    Filed: April 26, 2023
    Publication date: October 26, 2023
    Inventors: Nicholas P. GILL, Dean R. MADDEN, Moises CHAVEZ, Sahar AL-AYYOUBI, Patrick R. CUSHING, Yu ZHAO
  • NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
    Publication number: 20220169708
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 2, 2022
    Inventors: Bruce D. HAMMOCK, Natalia VASYLIEVA, Jiexian DONG, Christophe MORISSEAU, Dean R. MADDEN
  • Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
    Patent number: 11225514
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 18, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Bruce D. Hammock, Natalia Vasylieva, Jiexian Dong, Christophe Morisseau, Dean R. Madden
  • Dab2 inhibitors for the prevention and treatment of cystic fibrosis
    Patent number: 10864248
    Abstract: Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti-inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: December 15, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Dean R. Madden
  • Therapy and kit for the prevention and treatment of cystic fibrosis
    Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
    Publication number: 20200231659
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Application
    Filed: May 29, 2018
    Publication date: July 23, 2020
    Inventors: Bruce D. HAMMOCK, Natalia VASYLIEVA, Jiexian DONG, Christophe MORISSEAU, Dean R. MADDEN
  • Compounds and methods for inhibiting Cif virulence factor
    Patent number: 10322118
    Abstract: The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: June 18, 2019
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, THE REGENTS OF TE UNIVERSITY OF CALIFORNIA
    Inventors: Dean R. Madden, Christopher D. Bahl, Bruce D. Hammock, Christophe Morisseau
  • THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20180318382
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Application
    Filed: November 22, 2017
    Publication date: November 8, 2018
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • DAB2 INHIBITORS FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20170304392
    Abstract: Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.
    Type: Application
    Filed: November 11, 2015
    Publication date: October 26, 2017
    Inventor: Dean R. MADDEN
  • Therapy and kit for the prevention and treatment of cystic fibrosis
    Patent number: 9421239
    Abstract: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 23, 2016
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguérin, Rudolf Volkmer, Lars Vouilleme
  • COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR
    Publication number: 20160206605
    Abstract: The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
    Type: Application
    Filed: December 29, 2015
    Publication date: July 21, 2016
    Inventors: Dean R. Madden, Christopher D. Bahl, Bruce D. Hammock, Christophe Morisseau
  • Combination therapy and kit for the prevention and treatment of cystic fibrosis
    Patent number: 9333235
    Abstract: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: May 10, 2016
    Assignee: Trustees of Dartmouth College
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguérin, Rudolf Volkmer, Lars Vouilleme
  • THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20150250848
    Abstract: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.
    Type: Application
    Filed: May 22, 2015
    Publication date: September 10, 2015
    Applicant: Trustees of Dartmouth College
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguérin, Rudolf Volkmer, Lars Vouilleme
  • Small molecule conjugates with dimetal species for protein inhibition
    Patent number: 9045527
    Abstract: Methods for targeting a protein by providing an inhibitor covalently linked to a rhodium(II) complex, introducing the inhibitor to the target protein and allowing the inhibitor and protein to interact. The rhodium(II) complex covalently linked to the inhibitor binds the target protein both inorganically and organically and forms stabilizing secondary contacts between the rhodium(II) complex and the protein.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: June 2, 2015
    Assignees: WILLIAM MARSH RICE UNIVERSITY, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Zachary T. Ball, Rituparna Kundu, Brian V. Popp, Dean R. Madden, Patrick R. Cushing
  • Compositions and methods for inhibiting the interaction between CFTR and CAL
    Patent number: 8999919
    Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: April 7, 2015
    Assignee: Trustees of Dartmouth College
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguearin, Rudolph Volkmer, Lars Vouilleme
  • COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR
    Publication number: 20150045389
    Abstract: The present invention is a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compounds identified by the screening assay for use in compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
    Type: Application
    Filed: April 9, 2013
    Publication date: February 12, 2015
    Inventors: Dean R. Madden, Christopher D. Bahl, Bruce D. Hammock, Christophe Morisseau
  • COMBINATION THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20140100155
    Abstract: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.
    Type: Application
    Filed: December 13, 2013
    Publication date: April 10, 2014
    Applicant: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguérin, Rudolf Volkmer, Lars Vouilleme
  • SMALL MOLECULE CONJUGATES WITH DIMETAL SPECIES FOR PROTEIN INHIBITION
    Publication number: 20140011983
    Abstract: Methods for targeting a protein by providing an inhibitor covalently linked to a rhodium(II) complex, introducing the inhibitor to the target protein and allowing the inhibitor and protein to interact. The rhodium(II) complex covalently linked to the inhibitor binds the target protein both inorganically and organically and forms stabilizing secondary contacts between the rhodium(II) complex and the protein.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 9, 2014
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Zachary T. Ball, Rituparna Kundu, Brian V. Popp, Dean R. Madden, Patrick R. Cushing
  • Compositions and Methods for Inhibiting the Interaction Between CFTR and CAL
    Publication number: 20120071396
    Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 22, 2012
    Applicant: Trustees of Dartmouth College
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguearin, Rudolph Volkmer, Lars Vouilleme